Related Experiment Video
Updated: Jun 7, 2026
08:55
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
[Radionuclide therapy for neuroendocrine tumours]
Jann Mortensen1, Peter Oturai, Liselotte Højgaard
1Klinik for Klinisk Fysiologi, Nuklearmedicin og PET, Rigshospitalet, 2100 København Ø, Denmark. jann.mortensen@rh.regionh.dk
Ugeskrift for Laeger
|November 3, 2010
Summary
Peptide receptor radionuclide therapy with (177)Lu-DOTATATE offers benefits for neuroendocrine tumors. While generally safe with mild side effects, up to 20% of patients may not experience treatment effects.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiopharmacology
Background:
- Metastatic or inoperable neuroendocrine tumors (NETs) often require advanced treatment options.
- Somatostatin analogues labeled with beta-emitting isotopes represent a targeted therapy approach for NETs.
- Octreotide scintigraphy is crucial for identifying patients with increased somatostatin receptor expression.
Purpose of the Study:
- To review the principles, indications, and contraindications of peptide receptor radionuclide therapy (PRRT).
- To describe the practices and outcomes of (177)Lu-DOTATATE treatment at Rigshospitalet.
- To evaluate the efficacy and safety profile of PRRT in NET patients.
Main Methods:
- Review of treatment principles for somatostatin analogue-based PRRT.
- Analysis of patient selection criteria based on octreotide scintigraphy.
- Description of (177)Lu-DOTATATE administration protocols and observed outcomes.
Main Results:
- PRRT with (177)Lu-DOTATATE is indicated for NETs with confirmed increased octreotide uptake.
- The majority of patients experience improved quality of life and tumor stabilization or reduction.
- Side effects are typically mild and reversible, with severe long-term effects being rare.
Conclusions:
- PRRT using (177)Lu-DOTATATE is an effective treatment for selected patients with advanced neuroendocrine tumors.
- The therapy demonstrates a favorable safety profile, enhancing patient quality of life.
- A subset of patients (up to 20%) may not respond to this therapeutic approach.
